Implantable cardioverter-defibrillator therapy in primary versus secondary prevention: Reliable prediction of appropriate therapies and mortality is still an unmet need
Open Access
- 23 February 2021
- journal article
- editorial
- Published by Elsevier BV in IJC Heart & Vasculature
- Vol. 32, 100740
- https://doi.org/10.1016/j.ijcha.2021.100740
Abstract
No abstract availableKeywords
Funding Information
- National Institutes of Health
- German Research Foundation
- Japan Society for the Promotion of Science
This publication has 20 references indexed in Scilit:
- Contemporary rates of appropriate shock therapy in patients who receive implantable device therapy in a real-world setting: From the Israeli ICD RegistryHeart Rhythm, 2015
- Role of RyR2 Phosphorylation in Heart Failure and ArrhythmiasCirculation Research, 2014
- Role of electrical storm as a mortality and morbidity risk factor and its clinical predictors: a meta-analysisEP Europace, 2013
- Function and regulation of serine/threonine phosphatases in the healthy and diseased heartJournal of Molecular and Cellular Cardiology, 2013
- Ca 2+ -Related Signaling and Protein Phosphorylation Abnormalities Play Central Roles in a New Experimental Model of Electrical StormCirculation, 2011
- Long-term follow-up of primary and secondary prevention implantable cardioverter defibrillator patientsEP Europace, 2011
- Frequency and Causes of Implantable Cardioverter-Defibrillator Therapies: Is Device Therapy Proarrhythmic?The American Journal of Cardiology, 2006
- Differences in Tachyarrhythmia Detection and Implantable Cardioverter Defibrillator Therapy by Primary or Secondary Prevention Indication in Cardiac Resynchronization Therapy PatientsJournal of Cardiovascular Electrophysiology, 2004
- Heart Failure and the Risk of Shocks in Patients With Implantable Cardioverter DefibrillatorsCirculation, 2004
- Potential Benefit From Implantable Cardioverter-Defibrillator Therapy in Patients With and Without Heart FailureCirculation, 1998